257 related articles for article (PubMed ID: 14529363)
1. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease.
Lad SP; Neet KE; Mufson EJ
Curr Drug Targets CNS Neurol Disord; 2003 Oct; 2(5):315-34. PubMed ID: 14529363
[TBL] [Abstract][Full Text] [Related]
2. The cholinergic system, nerve growth factor and the cytoskeleton.
Niewiadomska G; Mietelska-Porowska A; Mazurkiewicz M
Behav Brain Res; 2011 Aug; 221(2):515-26. PubMed ID: 20170684
[TBL] [Abstract][Full Text] [Related]
3. APP, NGF & the 'Sunday-driver' in a Trolley on the Road.
Heese K; Inoue N; Nagai Y; Sawada T
Restor Neurol Neurosci; 2004; 22(2):131-6. PubMed ID: 15272147
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease.
Counts SE; Che S; Ginsberg SD; Mufson EJ
J Chem Neuroanat; 2011 Oct; 42(2):111-7. PubMed ID: 21397006
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration.
Capsoni S; Tiveron C; Vignone D; Amato G; Cattaneo A
Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12299-304. PubMed ID: 20566851
[TBL] [Abstract][Full Text] [Related]
6. Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.
Tiernan CT; Ginsberg SD; He B; Ward SM; Guillozet-Bongaarts AL; Kanaan NM; Mufson EJ; Counts SE
Neurobiol Dis; 2018 Sep; 117():125-136. PubMed ID: 29859871
[TBL] [Abstract][Full Text] [Related]
7. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.
Mufson EJ; Ma SY; Dills J; Cochran EJ; Leurgans S; Wuu J; Bennett DA; Jaffar S; Gilmor ML; Levey AI; Kordower JH
J Comp Neurol; 2002 Feb; 443(2):136-53. PubMed ID: 11793352
[TBL] [Abstract][Full Text] [Related]
8. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model.
Capsoni S; Brandi R; Arisi I; D'Onofrio M; Cattaneo A
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):635-47. PubMed ID: 21631402
[TBL] [Abstract][Full Text] [Related]
9. The cholinergic system in aging and neuronal degeneration.
Schliebs R; Arendt T
Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918
[TBL] [Abstract][Full Text] [Related]
10. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.
Mufson EJ; Counts SE; Perez SE; Ginsberg SD
Expert Rev Neurother; 2008 Nov; 8(11):1703-18. PubMed ID: 18986241
[TBL] [Abstract][Full Text] [Related]
11. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease.
Ginsberg SD; Che S; Wuu J; Counts SE; Mufson EJ
J Neurochem; 2006 Apr; 97(2):475-87. PubMed ID: 16539663
[TBL] [Abstract][Full Text] [Related]
12. Absence of p75(NTR) expression reduces nerve growth factor immunolocalization in cholinergic septal neurons.
Krol KM; Crutcher KA; Kalisch BE; Rylett RJ; Kawaja MD
J Comp Neurol; 2000 Nov; 427(1):54-66. PubMed ID: 11042591
[TBL] [Abstract][Full Text] [Related]
13. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease.
Ubhi K; Rockenstein E; Vazquez-Roque R; Mante M; Inglis C; Patrick C; Adame A; Fahnestock M; Doppler E; Novak P; Moessler H; Masliah E
J Neurosci Res; 2013 Feb; 91(2):167-77. PubMed ID: 23152192
[TBL] [Abstract][Full Text] [Related]
14. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease.
Cuello AC; Bruno MA; Bell KF
Curr Alzheimer Res; 2007 Sep; 4(4):351-8. PubMed ID: 17908036
[TBL] [Abstract][Full Text] [Related]
15. Focused ultrasound delivery of a selective TrkA agonist rescues cholinergic function in a mouse model of Alzheimer's disease.
Xhima K; Markham-Coultes K; Nedev H; Heinen S; Saragovi HU; Hynynen K; Aubert I
Sci Adv; 2020 Jan; 6(4):eaax6646. PubMed ID: 32010781
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies.
Xhima K; Markham-Coultes K; Hahn Kofoed R; Saragovi HU; Hynynen K; Aubert I
Brain; 2022 Aug; 145(8):2806-2822. PubMed ID: 34919633
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease.
Counts SE; Nadeem M; Wuu J; Ginsberg SD; Saragovi HU; Mufson EJ
Ann Neurol; 2004 Oct; 56(4):520-31. PubMed ID: 15455399
[TBL] [Abstract][Full Text] [Related]
19. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease.
Counts SE; Mufson EJ
J Neuropathol Exp Neurol; 2005 Apr; 64(4):263-72. PubMed ID: 15835262
[TBL] [Abstract][Full Text] [Related]
20. NGF and the Amyloid Precursor Protein in Alzheimer's Disease: From Molecular Players to Neuronal Circuits.
Triaca V; Ruberti F; Canu N
Adv Exp Med Biol; 2021; 1331():145-165. PubMed ID: 34453297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
